Lineage Cell Therapeutics, Inc. Amortization of Debt Discount (Premium)
Lineage Cell Therapeutics, Inc. (LCTX) reported Amortization of Debt Discount (Premium) of $640.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2019-03-14
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2017-06-30 was $387.00K, a 115.00% increase year-over-year.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2017-03-31 was $253.00K, a 289.23% increase year-over-year.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2017 was $640.00K, a 42.86% increase from fiscal 2016.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2016 was $448.00K, a 82.86% increase from fiscal 2015.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2015 was $245.00K, a 337.50% increase from fiscal 2014.
- Lineage Cell Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2014 was $56.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 3 month as first filed | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $0.00 derived: sum of 2 quarters · filed 2019-03-14 | $387.00K derived: sum of 3 quarters · filed 2019-03-14 | $640.00K 10-K · filed 2019-03-14 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $387.00K derived: sum of 2 quarters · filed 2018-11-08 | $640.00K 10-Q · filed 2018-11-08 | $824.00K derived: sum of 4 quarters · filed 2018-11-08 | |||
| 2017-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $640.00K 10-Q · filed 2018-08-02 | $824.00K derived: sum of 3 quarters · filed 2018-08-02 | $843.00K derived: sum of 4 quarters · filed 2018-08-02 | |||
| 2017-03-31 | $253.00K 10-Q · filed 2018-05-10 | $437.00K derived: sum of 2 quarters · filed 2018-05-10 | $456.00K derived: sum of 3 quarters · filed 2018-05-10 | $636.00K derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $203.00K derived: sum of 2 quarters · filed 2018-03-15 | $383.00K derived: sum of 3 quarters · filed 2018-03-15 | $448.00K 10-K · filed 2018-03-15 | |||
| 2016-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $199.00K derived: sum of 2 quarters · filed 2017-11-09 | $264.00K 10-Q · filed 2017-11-09 | $327.00K derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-06-30 | $180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $245.00K 10-Q · filed 2017-08-09 | $308.00K derived: sum of 3 quarters · filed 2018-03-15 | $371.00K derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2016-03-31 | $65.00K 10-Q · filed 2017-05-10 | $128.00K derived: sum of 2 quarters · filed 2018-03-15 | $191.00K derived: sum of 3 quarters · filed 2018-03-15 | $260.00K derived: sum of 4 quarters · filed 2018-03-15 | |||
| 2015-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $126.00K derived: sum of 2 quarters · filed 2018-03-15 | $195.00K derived: sum of 3 quarters · filed 2018-03-15 | $245.00K 10-K · filed 2018-03-15 | |||
| 2015-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $132.00K derived: sum of 2 quarters · filed 2016-11-04 | $182.00K 10-Q · filed 2016-11-04 | $234.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $119.00K 10-Q · filed 2016-08-09 | $171.00K derived: sum of 3 quarters · filed 2017-03-16 | $175.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $50.00K 10-Q · filed 2016-05-10 | $49.70K 10-Q · filed 2015-05-08 | $102.00K derived: sum of 2 quarters · filed 2017-03-16 | $106.00K derived: sum of 3 quarters · filed 2017-03-16 | $106.00K derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $56.00K derived: sum of 2 quarters · filed 2017-03-16 | $56.00K derived: sum of 3 quarters · filed 2017-03-16 | $56.00K 10-K · filed 2017-03-16 | $56.32K 10-K · filed 2015-03-11 | ||
| 2014-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $4.00K derived: sum of 2 quarters · filed 2015-11-09 | $4.00K 10-Q · filed 2015-11-09 | $3.67K 10-Q · filed 2014-11-07 | $4.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $0.00 derived: sum of 3 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 10-K · filed 2016-03-15 | |||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-07 | ||||||
| 2012-12-31 | $0.00 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |